Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 28;10(6):648.
doi: 10.3390/antibiotics10060648.

D-Penicillamine: The State of the Art in Humans and in Dogs from a Pharmacological and Regulatory Perspective

Michela Pugliese  1 , Vito Biondi  1 , Enrico Gugliandolo  1 , Patrizia Licata  1 , Alessio Filippo Peritore  2 , Rosalia Crupi  1 , Annamaria Passantino  1
Affiliations
Review

D-Penicillamine: The State of the Art in Humans and in Dogs from a Pharmacological and Regulatory Perspective

Michela Pugliese et al. Antibiotics (Basel). .

Abstract

Chelant agents are the mainstay of treatment in copper-associated hepatitis in humans, where D-penicillamine is the chelant agent of first choice. In veterinary medicine, the use of D-penicillamine has increased with the recent recognition of copper-associated hepatopathies that occur in several breeds of dogs. Although the different regulatory authorities in the world (United States Food and Drugs Administration-U.S. FDA, European Medicines Agency-EMEA, etc.) do not approve D-penicillamine for use in dogs, it has been used to treat copper-associated hepatitis in dogs since the 1970s, and is prescribed legally by veterinarians as an extra-label drug to treat this disease and alleviate suffering. The present study aims to: (a) address the pharmacological features; (b) outline the clinical scenario underlying the increased interest in D-penicillamine by overviewing the evolution of its main therapeutic goals in humans and dogs; and finally, (c) provide a discussion on its use and prescription in veterinary medicine from a regulatory perspective.

Keywords: D-penicillamine; copper-associated hepatitis; dog; humans; prescription.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Structure of D-penicillamine.
Figure 2
Figure 2
Evaluating the appropriateness of extra-label use (ELU) in dogs.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Weigert W.M., Offermanns H., Degussa P.S. D-Penicillamine? Production and Properties. Angew. Chem. Int. Ed. 1975;14:330–336. doi: 10.1002/anie.197503301. - DOI - PubMed
    1. Lipsky P.E., Ziff M. The effect of D-penicillamine on mitogen-induced human lymphocyte proliferation: Synergistic inhibition by D-penicillamine and copper salts. J. Immunol. 1978;120:1006–1013. - PubMed
    1. Lipsky P.E., Ziff M. Inhibition of Human Helper T Cell Function In Vitro by d-Penicillamine and CuSO4. J. Clin. Investig. 1980;65:1069–1076. doi: 10.1172/JCI109759. - DOI - PMC - PubMed
    1. Siegel R.C. Collagen cross-linking. Effect of D-penicillamine on cross-linking in vitro. J. Biol. Chem. 1977;252:254–259. doi: 10.1016/S0021-9258(17)32825-9. - DOI - PubMed
    1. Uitto J., Tan E.M.L., Ryhanen L. Inhibition of Collagen Accumulation in Fibrotic Processes: Review of Pharmacologic Agents and New Approaches with Amino Acids and Their Analogues. J. Investig. Dermatol. 1982;79:113s–120s. doi: 10.1111/1523-1747.ep12545951. - DOI - PubMed

LinkOut - more resources